 Regenxbio Inc NASDAQ: RGNX has announced a safety update and additional positive interim data from its ongoing Phase 12 trial of RGX-121 to treat patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II MPS II, also known as Hunter Syndrome. The data will be presented at the American Society of Gene and Cell Therapy 24th Annual Meeting. 